Health Care & Life Sciences » Biotechnology | Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc. | Ownership

Companies that own Atara Biotherapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
The Baupost Group LLC
6,254,632
13.79%
0
1.9%
06/30/2018
Fidelity Management & Research Co.
5,742,636
12.67%
-141,385
0.02%
06/30/2018
Redmile Group LLC
4,126,617
9.1%
-109,400
5.23%
06/30/2018
BlackRock Fund Advisors
3,042,943
6.71%
450,653
0.01%
06/30/2018
Bridger Management LLC
2,459,253
5.42%
-79,970
4.8%
06/30/2018
The Vanguard Group, Inc.
2,299,192
5.07%
753,001
0%
06/30/2018
SSgA Funds Management, Inc.
2,100,488
4.63%
92,421
0.01%
06/30/2018
Morgan Stanley & Co. LLC
2,014,776
4.44%
-82,434
0.1%
06/30/2018
T. Rowe Price Associates, Inc.
1,712,600
3.78%
19,647
0.01%
06/30/2018
Camber Capital Management LLC
1,620,000
3.57%
3,310
2.7%
06/30/2018

About Atara Biotherapeutics

View Profile
Address
611 Gateway Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.atarabio.com
Updated 07/08/2019
Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.